Publication

Deacetylase inhibitors in airway inflammation

Zwinderman, M., Cao, F. & Dekker, F., Oct-2019, Chemical Epigenetics. Mai, A. (ed.). Berlin: Springer Nature, p. 1-25

Research output: Chapter in Book/Report/Conference proceedingChapterProfessional

Copy link to clipboard

Documents

  • Acetylation and methylation in asthma, COPD and lung cancer

    Final author's version, 809 KB, PDF document

    Request copy

DOI

The urgent need for new therapies to treat airway inflammatory diseases is exemplified by the death of approximately 3 million patients suffering from chronic obstructive pulmonary disease (COPD) each year. Deranged intracellular signaling pathways in COPD, and in asthma alike, are critically regulated by protein posttranslational modifications (PTMs). Acetylation is one of the quintessential PTMs, found on over a thousand proteins and influencing a diverse range of protein properties. Firstly discovered on histones, their acetylation leads to a decrease in DNA-binding affinity and a concomitant increase in gene expression. Acetyltransferases and deacetylases, the enzymes that control acetylation, have been recognized as important drug targets and many deacetylase inhibitors have hence been developed. The deacetylase inhibitors that are currently evaluated in asthma and COPD show actions that go way beyond regulation of epigenetic mechanisms and inflammation, with deacetylase inhibitors even acting on airway smooth muscle contraction and motility. Distinct deacetylase isoforms are at play in each disease and potent isoform selective deacetylase inhibitors are thus highly needed and promising steps have been made in their development.
Original languageEnglish
Title of host publicationChemical Epigenetics
EditorsAntonello Mai
Place of PublicationBerlin
PublisherSpringer Nature
Pages1-25
Publication statusE-pub ahead of print - Oct-2019

View graph of relations

ID: 96886144